Summary of Anticoagulants: Direct coagulation factor inhibitors
Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI).
Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner") since it cannot be monitored by blood tests for international normalized ratio (INR) monitoring while offering similar results in terms of efficacy. There was no specific way to reverse the anticoagulant effect of dabigatran in the event of a major bleeding event at first, unlike warfarin.
Rivaroxaban is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Apixaban, sold under the tradename Eliquis, is a anticoagulant for the treatment of venous thromboembolic events. It is taken by mouth. It is a direct factor Xa inhibitor.
Flashcards on Anticoagulants: Direct coagulation factor inhibitors
Anticoagulants: Direct coagulation factor inhibitors
What is the most common adverse effect of Apixaban and Rivaroxaban (Factor Xa inhibitors)?